{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:42Z","timestamp":1790040342958,"version":"4.0.1"},"reference-count":141,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T00:00:00Z","timestamp":1602979200000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,7,17]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.<\/jats:p>","DOI":"10.1136\/jitc-2020-000810","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T17:30:36Z","timestamp":1603128636000},"page":"e000810","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02152956","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02674763","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02013167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02000427","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01471782","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01207388","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03214666","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02665065","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01830777","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04033302","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03904069","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04023071","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03876769","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael M","family":"Boyiadzis","sequence":"first","affiliation":[{"name":"Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Aksentijevich","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists, Fairfax, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Arber","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Barrett","sequence":"additional","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J","family":"Brentjens","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Brufsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Georgia Cancer Center, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"De Lima","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Forman","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J","family":"Fukas","sequence":"additional","affiliation":[{"name":"Clinical Research Services, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D","family":"Gore","sequence":"additional","affiliation":[{"name":"Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Pagel","sequence":"additional","affiliation":[{"name":"Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K","family":"Waller","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S","family":"Tallman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"2025100303555204000_8.2.e000810.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2025100303555204000_8.2.e000810.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2025100303555204000_8.2.e000810.3","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3026(17)30052-2","article-title":"Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89\u2008828 children from 198 registries in 53 countries","volume":"4","author":"Bonaventure","year":"2017","journal-title":"Lancet Haematol"},{"key":"2025100303555204000_8.2.e000810.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"2025100303555204000_8.2.e000810.5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0028"},{"key":"2025100303555204000_8.2.e000810.6","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.5858\/arpa.2016-0504-CP","article-title":"Initial diagnostic workup of acute leukemia: guideline from the College of American pathologists and the American Society of hematology","volume":"141","author":"Arber","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2025100303555204000_8.2.e000810.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112304"},{"key":"2025100303555204000_8.2.e000810.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278317"},{"key":"2025100303555204000_8.2.e000810.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.813"},{"key":"2025100303555204000_8.2.e000810.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-249128"},{"key":"2025100303555204000_8.2.e000810.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"2025100303555204000_8.2.e000810.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197905103001902"},{"key":"2025100303555204000_8.2.e000810.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-604546"},{"key":"2025100303555204000_8.2.e000810.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-674127"},{"key":"2025100303555204000_8.2.e000810.15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"key":"2025100303555204000_8.2.e000810.16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"2025100303555204000_8.2.e000810.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0460-5"},{"key":"2025100303555204000_8.2.e000810.18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","article-title":"Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia","volume":"10","author":"Wei","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2025100303555204000_8.2.e000810.19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ebiom.2019.08.025","article-title":"Mdsc targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers","volume":"47","author":"Fultang","year":"2019","journal-title":"EBioMedicine"},{"key":"2025100303555204000_8.2.e000810.20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783"},{"key":"2025100303555204000_8.2.e000810.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"2025100303555204000_8.2.e000810.22","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0188-z"},{"key":"2025100303555204000_8.2.e000810.23","doi-asserted-by":"crossref","unstructured":"Graham R , Mancher M , Wolman DM , et al Graham R , Mancher M , Wolman DM , et al , eds. Institute of medicine. clinical practice guidelines we can trust. Washington, DC: The National Academies Press, 2011: 290.","DOI":"10.17226\/13058"},{"key":"2025100303555204000_8.2.e000810.24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.18.01468","article-title":"Initial diagnostic work-up of acute leukemia: ASCO clinical practice guideline endorsement of the College of American pathologists and American Society of hematology guideline","volume":"37","author":"de Haas","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100303555204000_8.2.e000810.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498"},{"key":"2025100303555204000_8.2.e000810.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw025"},{"key":"2025100303555204000_8.2.e000810.27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.blre.2017.01.003","article-title":"Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia","volume":"31","author":"Percival","year":"2017","journal-title":"Blood Rev"},{"key":"2025100303555204000_8.2.e000810.28","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"2025100303555204000_8.2.e000810.29","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol"},{"key":"2025100303555204000_8.2.e000810.30","unstructured":"Pfizer . MYLOTARG perscribing information New York City, NY. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf"},{"key":"2025100303555204000_8.2.e000810.31","unstructured":"Amgen . BLINCYTO perscribing information thousand oaks. Available: https:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/blincyto\/blincyto_pi_hcp_english.pdf"},{"key":"2025100303555204000_8.2.e000810.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"2025100303555204000_8.2.e000810.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100303555204000_8.2.e000810.34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"G\u00f6kbuget","year":"2019","journal-title":"Hematology"},{"key":"2025100303555204000_8.2.e000810.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716863"},{"key":"2025100303555204000_8.2.e000810.36","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025100303555204000_8.2.e000810.37","article-title":"A phase I, first-in-human study of MGD006\/S80880 (CD123 X CD3 dart) in AML\/MDS","volume":"35","author":"Vey","year":"2017","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.38","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112891","article-title":"Maturing clinical profile of IMGN779, a next-generation CD33-Targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.39","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0147"},{"key":"2025100303555204000_8.2.e000810.40","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115252","article-title":"Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of Tisagenlecleucel","volume":"132","author":"Schuster","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.379.379","article-title":"Blast: a confirmatory, single-arm, phase 2 study of Blinatumomab, a bispecific T-cell Engager (BiTE\u00ae) antibody construct, in patients with minimal residual disease B-Precursor acute lymphoblastic leukemia (all)","volume":"124","author":"Goekbuget","year":"2014","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.42","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2147\/DDDT.S150317","article-title":"Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"12","author":"Yurkiewicz","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2025100303555204000_8.2.e000810.43","unstructured":"Pfizer . BESPONSA perscribing information New York City, NY. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf"},{"key":"2025100303555204000_8.2.e000810.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035"},{"key":"2025100303555204000_8.2.e000810.45","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of Tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.46","unstructured":"Novartis . Kymriah package insert. FDA US, 2017."},{"key":"2025100303555204000_8.2.e000810.47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402552"},{"key":"2025100303555204000_8.2.e000810.48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-580027"},{"key":"2025100303555204000_8.2.e000810.49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615757"},{"key":"2025100303555204000_8.2.e000810.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710"},{"key":"2025100303555204000_8.2.e000810.51","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0690-8"},{"key":"2025100303555204000_8.2.e000810.52","doi-asserted-by":"crossref","unstructured":"Brown PA , Wieduwilt M , Logan A , et al . NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2019 2019;17:414.","DOI":"10.6004\/jnccn.2019.0024"},{"key":"2025100303555204000_8.2.e000810.53","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/bjh.14923","article-title":"Donor-Derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation","volume":"179","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"key":"2025100303555204000_8.2.e000810.54","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"2025100303555204000_8.2.e000810.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"2025100303555204000_8.2.e000810.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202"},{"key":"2025100303555204000_8.2.e000810.57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100303555204000_8.2.e000810.58","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"2025100303555204000_8.2.e000810.59","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2025100303555204000_8.2.e000810.60","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U"},{"key":"2025100303555204000_8.2.e000810.61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"2025100303555204000_8.2.e000810.62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"2025100303555204000_8.2.e000810.63","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.159343"},{"key":"2025100303555204000_8.2.e000810.64","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2016.01.019","article-title":"A phase I study of Reduced-Intensity conditioning and allogeneic stem cell transplantation followed by dose escalation of targeted consolidation immunotherapy with Gemtuzumab Ozogamicin in children and adolescents with CD33+ acute myeloid leukemia","volume":"22","author":"Zahler","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100303555204000_8.2.e000810.65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z"},{"key":"2025100303555204000_8.2.e000810.66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808777"},{"key":"2025100303555204000_8.2.e000810.67","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000445"},{"key":"2025100303555204000_8.2.e000810.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0811036"},{"key":"2025100303555204000_8.2.e000810.69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053"},{"key":"2025100303555204000_8.2.e000810.70","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.7"},{"key":"2025100303555204000_8.2.e000810.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.030"},{"key":"2025100303555204000_8.2.e000810.72","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2018.12.764","article-title":"Low-Dose azacitidine with DNMT1 level monitoring to treat post-transplantation acute myelogenous leukemia or myelodysplastic syndrome relapse","volume":"25","author":"Ueda","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100303555204000_8.2.e000810.73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100303555204000_8.2.e000810.74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"2025100303555204000_8.2.e000810.75","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of acute myeloid leukemia","volume":"13","author":"Guy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"2025100303555204000_8.2.e000810.76","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-109762","article-title":"A phase 1 first-in-human study of AMG 330, an Anti-CD33 bispecific T-cell Engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.77","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111529","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33\/CD3 T-cell Engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"132","author":"Westervelt","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.78","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7048","article-title":"Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131 I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial","volume":"37","author":"Tomlinson","year":"2019","journal-title":"JCO"},{"key":"2025100303555204000_8.2.e000810.79","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112955","article-title":"A phase I, first-in-human study evaluating the safety and preliminary antileukemia activity of IMGN632, a novel CD123-Targeting antibody-drug conjugate, in patients with relapsed\/refractory acute myeloid leukemia and other CD123-Positive hematologic malignancies","volume":"132","author":"Daver","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.80","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cncr.32657","article-title":"A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed\/refractory acute myeloid leukemia","volume":"126","author":"Narayan","year":"2020","journal-title":"Cancer"},{"key":"2025100303555204000_8.2.e000810.81","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111845","article-title":"Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (all): preliminary results of a phase I study","volume":"132","author":"Webster","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.82","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774"},{"key":"2025100303555204000_8.2.e000810.83","article-title":"Nivolumab (Nivo) with Azacytidine (aza) in patients (PTS) with relapsed acute myeloid leukemia (AML) or frontline elderly AML","volume":"130","author":"Daver","year":"2017","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.84","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025100303555204000_8.2.e000810.85","article-title":"Phase II study of high dose cytarabine followed by pembrolizumab in relapsed\/refractory acute myeloid leukemia (AML)","volume":"130","author":"Zeidner","year":"2017","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.86","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131494","article-title":"Azacitidine (aza) with nivolumab (Nivo), and aza with Nivo + ipilimumab (IPI) in relapsed\/refractory acute myeloid leukemia: a Non-Randomized, prospective, phase 2 study","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.87","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-LB-146","article-title":"Abstract LB-146: phase I CD22 CAR T-cell trial updates","volume":"79","author":"Shah","year":"2019","journal-title":"Cancer Res"},{"key":"2025100303555204000_8.2.e000810.88","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"Cd22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"2025100303555204000_8.2.e000810.89","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-Specific CAR T cells: a first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.90","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2535.2535","article-title":"Infusion of donor lymphocytes genetically engineered to express the herpes simplex virus thymidine kinase (HSV-tk) suicide gene after haploidentical hematopoietic stem cell transplantation (HSCT): preliminary efficacy data from the randomized TK008 study","volume":"124","author":"Bonini","year":"2014","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341"},{"key":"2025100303555204000_8.2.e000810.92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004916"},{"key":"2025100303555204000_8.2.e000810.93","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0472-9"},{"key":"2025100303555204000_8.2.e000810.94","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-020-01741-4","article-title":"Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies","volume":"11","author":"Shankar","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"2025100303555204000_8.2.e000810.95","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood.2019002132","article-title":"How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy","volume":"135","author":"Aldoss","year":"2020","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-019-0705-x","article-title":"Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100303555204000_8.2.e000810.97","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 X CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.98","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-114415","article-title":"A feasibility and safety study of CD19 and CD22 chimeric antigen receptors-modified T cell cocktail for therapy of B cell acute lymphoblastic leukemia","volume":"132","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"2025100303555204000_8.2.e000810.99","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025100303555204000_8.2.e000810.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100303555204000_8.2.e000810.101","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"2025100303555204000_8.2.e000810.102","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3497-0"},{"key":"2025100303555204000_8.2.e000810.103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100303555204000_8.2.e000810.104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"2025100303555204000_8.2.e000810.105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100303555204000_8.2.e000810.106","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1585238"},{"key":"2025100303555204000_8.2.e000810.107","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"2025100303555204000_8.2.e000810.108","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1025"},{"key":"2025100303555204000_8.2.e000810.109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"2025100303555204000_8.2.e000810.110","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"2025100303555204000_8.2.e000810.111","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524"},{"key":"2025100303555204000_8.2.e000810.112","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"2025100303555204000_8.2.e000810.113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"2025100303555204000_8.2.e000810.114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in car T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025100303555204000_8.2.e000810.115","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100303555204000_8.2.e000810.116","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100303555204000_8.2.e000810.117","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100303555204000_8.2.e000810.118","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100303555204000_8.2.e000810.119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100303555204000_8.2.e000810.120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.03.005"},{"key":"2025100303555204000_8.2.e000810.121","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1188\/15.ONF.E91-E101","article-title":"Patient-Reported symptoms and quality of life in adults with acute leukemia: a systematic review","volume":"42","author":"Leak Bryant","year":"2015","journal-title":"Oncol Nurs Forum"},{"key":"2025100303555204000_8.2.e000810.122","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.blre.2017.08.010","article-title":"Patient-Reported outcomes in acute myeloid leukemia: where are we now?","volume":"32","author":"Buckley","year":"2018","journal-title":"Blood Rev"},{"key":"2025100303555204000_8.2.e000810.123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804658"},{"key":"2025100303555204000_8.2.e000810.124","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-Reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"2025100303555204000_8.2.e000810.125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","author":"Tran","year":"2018","journal-title":"Ann Transl Med"},{"key":"2025100303555204000_8.2.e000810.126","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-Term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"key":"2025100303555204000_8.2.e000810.127","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/13696998.2017.1344127","article-title":"Cost-Effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective","volume":"20","author":"Delea","year":"2017","journal-title":"J Med Econ"},{"key":"2025100303555204000_8.2.e000810.128","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40273-019-00779-4","article-title":"The clinical and cost effectiveness of Inotuzumab Ozogamicin for the treatment of adult relapsed or refractory B-cell acute lymphoblastic leukaemia: an evidence review group evaluation of a NICE single technology appraisal","volume":"37","author":"Cox","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"2025100303555204000_8.2.e000810.129","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31551"},{"key":"2025100303555204000_8.2.e000810.130","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"},{"key":"2025100303555204000_8.2.e000810.131","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019034"},{"key":"2025100303555204000_8.2.e000810.132","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1006"},{"key":"2025100303555204000_8.2.e000810.133","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-016-0447-x","article-title":"Estimating long-term survival of adults with Philadelphia chromosome-negative relapsed\/refractory B-Precursor acute lymphoblastic leukemia treated with Blinatumomab using historical data","volume":"34","author":"Barlev","year":"2017","journal-title":"Adv Ther"},{"key":"2025100303555204000_8.2.e000810.134","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"2025100303555204000_8.2.e000810.135","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-Precursor acute lymphoblastic leukemia following treatment with Blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100303555204000_8.2.e000810.136","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100303555204000_8.2.e000810.137","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"2025100303555204000_8.2.e000810.138","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"2025100303555204000_8.2.e000810.139","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"2025100303555204000_8.2.e000810.140","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"2025100303555204000_8.2.e000810.141","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.3628"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:56:04Z","timestamp":1759488964000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,19]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jitc-2020-000810"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000810","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}